Showing 15 posts of 111 posts found.

Eisai image

FDA approves Eisai’s chemo side-effects drug

October 15, 2014
Research and Development, Sales and Marketing Eisai, FDA, Helsinn, akynzeo, chemotherapy, cinv

Eisai and Helsinn Healthcare’s Akynzeo (netupitant/palonosetron) has received FDA approval for the treatment of chemotherapy-induced nausea and vomiting (CINV). CINV …

ABPI image

ABPI and BIA establish new manufacturing partnership

September 23, 2014
Manufacturing and Production, Sales and Marketing ABPI, Actavis, AstraZeneca, BIA, Eisai, Fujifilm Diosynth Biotechnologies, GlaxoSmithKline, Knowledge Transfer Network (KTN), Oxford BioMedica, Pfizer, Whitehead, bates, mmip

The ABPI and the Bioindustry Association (BIA) have jointly established a new Medicines Manufacturing Industry Partnership (MMIP) to boost medicines …

Priddy image

Alzheimer’s disease: pharma’s greatest challenge

April 4, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AD, Alzheimer's, Alzheimer’s, Eisai, Lunt, Pfizer, galantamine, karran, priddy

Like it or not, we are all becoming increasingly prone to a currently incurable and debilitating disease, that places an …

Biogen image

Alzheimer’s tie-up for Eisai and Biogen

March 6, 2014
Research and Development, Sales and Marketing Alzheimer's, BAN2401, Biogen IDEC, E2609, Eisai

Eisai and Biogen Idec have joined forces to look for new Alzheimer’s treatments, developing and commercialising two of the Japanese …

Eisai image

Eisai reorganises R&D

December 2, 2013
Research and Development, Sales and Marketing Eisai, R&D, cfu, epcs, pcu, reorganisation

Tokyo-based Eisai is to axe 130 jobs in Europe and the US as part of an attempt to shake up …

eisai image

Eisai signs tropical disease deal

November 12, 2013
Research and Development, Sales and Marketing Disease, Eisai, Japan, broad, ntd, tropical

Eisai has become the latest pharma firm to partner with the US-based Broad Institute to pool expertise and come up …

Eisai image

Eisai: reform NICE or we’ll pull out of the UK

October 21, 2013
Research and Development, Sales and Marketing Eisai, Hatfield, Hunt, NICE

Eisai has criticised NICE for being too narrow minded on assessing new drugs, and has warned it may pull its …

Eisai image

Eisai backs disease fund

July 12, 2013
Research and Development, Sales and Marketing Eisai, Japan, TB, partnership

A leading Japanese pharma group says that the sector should see investment in fighting diseases of the developing world as …

Eisai image

Eisai’s £8 million UK expansion

June 17, 2013
Manufacturing and Production Eisai

Eisai has decided to invest further into its Hertfordshire production plant in the UK towards the creation of an additional …

Eisai appoints chief clinical officer

April 12, 2013
Manufacturing and Production, Research and Development, Sales and Marketing Eisai

Eisai has announced the immediate appointment of Lynn Kramer to the newly created position of chief clinical officer of Eisai …

Pharma manufacturing news in brief

March 11, 2013
Business Services, Manufacturing and Production Actavis, DSM, Eisai, J&J, JJ, Marken, SAFC, Sagent Pharma

Actavis revises supply deal with Sagent, facility updates from Marken and SAFC, a supply deal for DSM plus another J&J …

Eisai image

Eisai cancer drug fails

January 14, 2013
Research and Development, Sales and Marketing Cancer, Eisai, Morphotek, farletuzumab

Eisai’s investigational oncology treatment farletuzumab has failed to reach its primary endpoint in a late-stage trial. Farletuzumab (MORAb-003) did not …

Eisai image

Eisai and Novartis part ways

January 8, 2013
Sales and Marketing COPD, Eisai, Novartis, Onbrez, Spiriva

Novartis and Eisai have abandoned their co-promotion agreement for three of Novartis’ chronic obstructive pulmonary disease treatments. The move follows …

Pharma manufacturing news in brief

December 21, 2012
Manufacturing and Production Amarin, BASF, Bioden Idec, Eisai, Lonza, Patheon, Sartorious Stedim Biotech, banner pharmacaps

BASF extends offer for ProNova, Patheon closes Banner Pharmacaps deal, plus updates from Amarin, Biogen Idec/Eisai and Lonza.

Eisai image

SMC first to give Fycompa thumbs-up

December 12, 2012
Sales and Marketing Eisai, Fycompa, SMC, Scotland, epilepsy

The Scottish Medicines Consortium (SMC) has approved Eisai’s first-in-class epilepsy drug Fycompa for use in the NHS in Scotland – …

Latest content